Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis

Exclusion Criteria

• •1. Other type of psoriasis (e.g. erythrodermic, guttate or pustular) at enrolment
• •2. Drug induced psoriasis at enrolment (e.g. lithium)
• •3. Pregnant or lactating women, patients (men or women) planning a pregnancy during the duration of the study
• •4. Systemic therapy affecting PASI or phototherapy for a period of 4 weeks prior to enrolment
• •5. Topical therapy affecting PASI for a period of 2 weeks prior to enrolment
• •6. Treatment with biologic agents affecting PASI for a period of 3 months prior to enrolment
• •7. Systemic treatment with immunosuppressive agents (e.g. methotrexate, cyclosporin) or treatment with lithium, anti-malaria medication, or intramuscular gold application for a period of 4 weeks prior to enrolment
• •8. Having a history of or an ongoing uncontrolled serious or recurring bacterial, viral, fungal, or atypical mycobacterial infection
• •9. Having a severe medical condition that, in the judgment of the investigator, would jeopardize in any way the subject's safety following exposure to study drug
• •10. Having the presence or history of malignancy, including lymphoproliferative disorders. Subjects with a history of fully resolved basal or squamous cell skin cancer may be enrolled